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Carotid endarterectomy (CEA) has been estab-
lished as the standard treatment for high-grade
stenosis of the extracranial carotid arteries.1,2
During the course of the review of this heavily
scrutinized operation over the past 40 years, new
methods of revascularization have recently been
explored. Percutaneous transluminal angioplasty
of the extracranial carotid artery has been reported
since 1983,3-8 and more recently angioplasty with
stenting has been advocated as an alternative treat-
ment for both symptomatic and asymptomatic lesions
of the carotid bifurcation.9,10 Concern about the safe-
ty of this procedure has been expressed in the medical
literature.11,12 Rationale for this approach hypotheti-
cally includes less morbidity, shorter recovery, and
lower cost when compared with CEA. We have previ-
ously reported on a series of percutaneous translumi-
nal angioplasty with stenting (PTAS) of the carotid
artery to evaluate its safety.9 We have further com-
pared the results of PTAS with the results of CEA for
a concurrent group of patients treated at our institu-
tion.13 To further outline the role for PTAS and the
treatment of this disease, we then undertook a
detailed cost analysis of these two groups of patients.
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Purpose: Percutaneous transluminal angioplasty with stenting (PTAS) of the carotid
artery has been advocated as an alternative treatment for high-grade stenosis. Rationale
for this approach includes less morbidity, shorter recovery, and lower cost when com-
pared with carotid endarterectomy (CEA).
Methods: The clinical results and hospital charges of patients who underwent elective
treatment for carotid stenosis were reviewed. During a concurrent 14-month period,
218 patients were admitted 229 times for 234 procedures for the treatment of 239
carotid bifurcation stenoses, 109 by PTAS and 130 by CEA. Hospital charges were
reviewed for each hospitalization and were categorized according to radiology, operat-
ing room, cardiac catheterization laboratory, and all other hospital charges.
Results: The combined incidence of postprocedure strokes and deaths were: PTAS, eight
strokes (7.7%) and one death (0.9%); CEA, two strokes (1.5%) and two deaths (1.5%).
Total hospital charges per admission for the two groups were $30,140 for PTAS and
$21,670 for CEA. The average postprocedure length of stay for PTAS was 2.9 days
(median, 2 days) and for CEA was 3.1 days (median, 3 days). Cardiac catheterization
laboratory charges for the PTAS group were $12,968, whereas the operating room
charges for the CEA group were $4263. When hospitalizations that were extended by
complications were excluded, the average total charges for the PTAS group (n = 84)
dropped to $24,848 (mean length of stay, 1.9 days) and for the CEA group (n = 111)
to $19,247 (mean length of stay, 2.6 days).
Conclusions: After evaluating hospital charges, PTAS for the treatment of carotid steno-
sis cannot currently be justified on the basis of reduced costs alone. With future cost-
containing measures, total hospital charges can be reduced in both groups. (J Vasc Surg
1998;27:16-24.)
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METHODS
A retrospective review was performed of all
patients who underwent elective treatment of
carotid artery stenosis between August 1994 and
October 1995 at the University of Alabama at
Birmingham Hospital. Patients were assigned to
each group according to referral patterns without
randomization. No patients in the PTAS group were
referred by these surgical authors because of “high-
risk” CEA, such as high lesions, or a “hostile” neck.
Clinical data had been initially prospectively gath-
ered in both the PTAS and the CEA groups, but fur-
ther review, specifically financial data, was obtained
in a retrospective fashion to match hospital admis-
sions with a generated charge from the hospital busi-
ness office. Patients whose charge data could not be
matched with an admission were excluded from fur-
ther analysis (PTAS, seven patients; CEA, two
patients). Charge data were tracked and assessed
because of its immediate availability (versus actual
cost data). The hospital charges were then subse-
quently reviewed and categorized according to per-
tinent groups for these patients: radiology, operating
room, cardiac catheterization, and all other hospital
charges. All diagnostic imaging studies are classified
under radiology with the exception of intraoperative
arteriography, which is classified under operating
room charges. Additional hospital charges, including
medications, room and board, and ancillary services,
are classified under all other hospital charges. No
professional fees are included in these tabulations.
Additional diagnostic radiologic charges that may be
categorized with the PTAS investigative trial are also
listed under radiology charges. No specific measures
were undertaken in either group for the purpose of
limiting costs.
The two groups were further subcategorized
with regard to the therapeutic portion of their hos-
pitalization. Specifically, cardiac catheterization lab-
oratory charges, including stents, guiding catheters,
and balloon catheters for the PTAS group, were
compared with the operating room charges, includ-
ing electroencephalographic monitoring and pros-
thetic patches, for the CEA group. The sum of
catheterization laboratory and operating room
charges are considered the procedural charge to
allow comparison with the therapeutic portion of
the hospitalization. On rare occasions, if patients
had bilateral stenoses treated during one procedure,
the treatment was counted as a single procedure
(PTAS, three patients; CEA, 0 patients). If a patient
had bilateral carotid stenoses treated at two separate
procedures during the same hospitalization, the total
hospitalization charges were averaged between the
two procedures (PTAS, 0 patients; CEA, five
patients, 10 procedures). This calculation was done
to compare mean charges per procedure as two sep-
arate procedures (e.g., a single patient who under-
went bilateral CEA performed at a 5-day interval
during the same hospitalization for a total charge of
$40,000 was calculated as $20,000 per procedure).
The clinical data regarding this comparison have
been previously published but are summarized here
for further understanding regarding the costs.9,13
The PTAS group underwent the procedure in the
cardiac catheterization laboratory and were then
transferred to an intermediate care unit for monitor-
ing. Routine discharge occurred on postprocedure
day one if the patient was clinically stable. The CEA
patients underwent operation with various monitor-
ing techniques according to the surgeons’ prefer-
ence: regional anesthesia, general anesthesia with
electroencephalographic monitoring and transcra-
nial Doppler monitoring for selective shunting, and
general anesthesia with electroencephalographic
monitoring and burst suppression. The use of intra-
operative monitoring equipment and the intensive
care unit was dictated by the surgeon or interven-
tionalist at the time of the procedure.
Total hospitalization days were also assessed.
Because of inconsistent preprocedure admission days
as a result of nonstandardized evaluations, postpro-
cedure length of stay was tracked to evaluate the
recovery needed after each procedure. If bilateral
Table I, A. Patient characteristics
PTAS  CEA
(98 patients) (120 patients) p
Mean age (yr) 70 (35 to 87) 67 (41 to 83)
Male 68 (69%) 71 (59%) 0.123
Caucasian 94 (96%) 113 (94%) 0.758
Coronary artery 
disease 68 (69%) 63 (53%) 0.013
Hypertension 80 (82%) 78 (65%) 0.006
Diabetes 27 (28%) 22 (18%) 0.142
Smoking history 64 (65%) 87 (73%) 0.302
Table I, B. Indications for treatment
PTAS CEA
(109 sides) (130 sides) p
Asymptomatic 44 (40%) 53 (41%) 0.917
Transient ischemic 
attack 37 (34%) 68 (52%) 0.015
Cerebrovascular 
accident 28 (26%)          9 (7%) <0.001
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lesions were treated at two separate procedures
under one admission, then postoperative length of
stay was tallied from the date of the second proce-
dure. Preprocedure days are also reported to appre-
ciate that influence on the total hospital charges.
Patients who are initially admitted for one method
of treatment but crossed over to the other group
were excluded from this analysis (PTAS, two
patients; CEA, one patient).
A comparison between a group of patients who
had no preprocedure or postprocedure complica-
tions was evaluated to analyze the lowest operating
costs for these treatment methods. Any patients in
whom postprocedure complications developed or
who required additional procedures that extended
hospitalization beyond 4 postprocedure days (>2
standard deviations above mean), or any patients
who underwent bilateral carotid procedures during
one hospitalization, were considered complicated
admissions.
To examine for significant differences of the total
cost of hospitalization, radiology charges, cardiac
catheterization laboratory charges, operating room
charges, other hospital charges, and postprocedure
length of hospitalization, two sample t tests were
used to compare the CEA procedures (n = 130) with
the PTAS procedures (n = 104) using SAS comput-
er software (Cary, N.C.). On further analyses of the
uncomplicated group, multiple linear regression was
used to compare the total cost of hospitalization
between the groups after adjusting for the length of
hospitalization. Examination for outliers, leverage,
and influential points that could overly impact the
estimation of multiple linear regression was con-
ducted for this uncomplicated group. Fisher’s exact
test was used for comparison of proportions.
RESULTS
Two hundred eighteen patients were admitted
229 times for 234 different procedures involving the
treatment of 239 carotid bifurcation stenoses. Table
I outlines the patient characteristics and indications
for each group; it shows a similarity of the risk fac-
tors that are often associated with carotid stenosis
along with a significantly greater number of patients
with coronary artery disease and hypertension in the
PTAS group. Although patient characteristics are
categorized according to each patient, subsequent
analyses were evaluated according to procedures.
Excluding patients who had a hospitalization that
was extended as a result of complications or addi-
tional procedures, there were a total of 185 patients
who were admitted 195 times for 195 procedures,
84 for the PTAS group and 111 in the CEA group.
Exclusion criteria for the uncomplicated group are
listed in Table II.
Clinical results. Neurologic deficits that lasted
greater than 24 hours occurred after eight of 104
PTAS procedures (7.7%) and after four of 130 CEA
procedures (3.1%). One death occurred after a PTAS
procedure (0.9%), and two neurologic deaths
occurred after CEA procedures (1.5%). Six of the
eight strokes in the PTAS group were classified as
minor because of minimal deficit evident at 30 days.
One of the CEA patients had a minor stroke. The
total rate of stroke and death was 8.7% for the PTAS
group and 3.1% for the CEA group (p = 0.085).
The incidence of nonneurologic morbidity was
also greater in the PTAS group and included acute
renal failure (1), hematoma (2), lower extremity
ischemia related to iliac artery dissection (1),
myocardial infarction (1), permanent pacemaker (1),
and respiratory failure (1)—a total of seven compli-
cations in six of 98 patients (6.1%). One patient in
the CEA group had a myocardial infarction that
required heparin and a subsequent neck hematoma
that required drainage—a total of two complications
in one of 120 patients (0.8%).
Costs. The average total hospital charge for the
PTAS group was $30,140, whereas the average
charge for the CEA group was $21,670. These
charges are further subcategorized according to
radiology charges, operating room charges, cardiac
catheterization laboratory charges, and all other hos-
pital charges (Fig. 1). Operating room charges for
the CEA group were less expensive compared with
cardiac catheterization charges for the PTAS group
(p = 0.0001). Radiology charges were also greater
for the PTAS group (p = 0.0042). Other hospital
charges, including room, board, pharmacy, and
additional services related to length of stay, were
greater for the CEA group, although significance
Table II. Exclusions from the uncomplicated
group
PTAS procedures CEA procedures 
(n = 104) (n = 130)
Neurologic deficit 4 4
Bilateral carotid procedures 3 10
Additional procedures 3 2
Extra hospital days 10 3
Uncomplicated procedures 84 (80.8%)* 111 (85.4%)*
*p = 0.380.
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Fig. 3. Total preprocedural and postprocedural hospital
days for the total groups and the uncomplicated groups.
was not reached (p = 0.1719). Total hospitalization
costs related to procedure type and length of hospi-
talization using regression line analysis is demon-
strated in Fig. 2. The slopes of the regression lines
are the same between the two groups, representing
a per-day hospitalization charge of $2402. The ini-
tial charge (y-intercept) was $20,416 for the PTAS
group and $13,101 for the CEA group.
The postprocedure length of stay for the PTAS
group was shorter than for the CEA group (2.9 vs
3.1 days) but did not reach significance (p = 0.6468;
Fig. 3). The median postprocedure length of stay
was 2 days for the PTAS group and 3 days for the
CEA group. Hospitalization charges associated with
this length of stay were not significantly higher for
the CEA group—$12,995 vs $10,491 for the PTAS
group (p = 0.1719; Fig. 1).
Uncomplicated admissions were analyzed for
each group: 84 in the PTAS group and 111 in the
CEA group. Charges for the uncomplicated PTAS
group were $24,848 vs $19,247 for the uncompli-
cated CEA group. The mean length of stay for the
patients in the uncomplicated group was significant-
ly less at 1.8 postprocedure days in the PTAS group
and 2.6 postprocedure days in the CEA group (p =
0.0001; Fig. 3). Procedure charges (sum of operat-
ing room and cardiac catheterization laboratory) for
this uncomplicated group demonstrated that PTAS
admissions averaged $11,957, whereas CEA admis-
sions averaged $4415 (p = 0.0001). Fig. 4 compares
the uncomplicated admissions with the complicated
admissions within each group.
DISCUSSION
Theoretically, justification for consideration of
extracranial carotid balloon angioplasty includes
potentially reduced morbidity rate, reduced cost,
shortened hospitalization, and improved long-term
patency rates. CEA has been well established as a
proved operation with a durable result. Vigorous
scrutiny must be applied to any new procedure that
challenges this established treatment method. This
series represents a focused effort to evaluate our
experience with PTAS and CEA to compare the cost
of these two procedures at a single institution. There
have been no specific cost-containing measures used
in either group. Furthermore, PTAS is currently per-
formed under Institutional Review Board–guided
Fig. 2. Regression line compares hospital charges as a
function of procedure and postprocedure hospital stay for
patients with uncomplicated cases in each group.
Fig. 1. Hospital charges for all admissions for each group
of patients are compared.
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ing room. Procedural times are somewhat similar
between the two groups, with an experiential reduc-
tion in the time required in the cardiac catheteriza-
tion procedure towards the latter part of this series.
No significant reduction in the charges for the pro-
cedure can be identified over this series of 98 proce-
dures. The cost analysis of the complicated group
with the uncomplicated group did identify a large
difference ($7994) in the procedural costs for the
complicated PTAS group compared with an insignif-
icant difference for the CEA group. Thus the com-
plicated PTAS case can be identified during the pro-
cedure. Breakdown of these higher expenses in the
catheterization laboratory was not performed but
may be related to the costs of stents, angioplasty bal-
loons, catheters, and pacemakers. Further examina-
tion of the uncomplicated groups, or the “best case
scenario,” reveals an increase of $1280 between the
radiology charges of PTAS and CEA (Fig. 4). When
considering a similar use of arteriography between
these groups, this higher charge likely represents the
additional tests (magnetic resonance imaging and
single proton emission computed tomographic scan)
that might not be required if PTAS can become an
established clinical method.
When our surgical community is charged with
evaluating new methods of treatment, we must con-
sider the available data before embarking on a ran-
domized prospective clinical trial. The current
method of evaluating new forms of therapy includes
careful scrutiny of the safety and efficacy of such
therapy in light of established therapy that is cur-
rently available. If near equivalency can be estab-
research protocol and involves some additional test-
ing, such as routine magnetic resonance imaging
and single proton emission computed tomographic
scans, that might not eventually be required if this
procedure becomes established in its technical fea-
tures. The features of short-term morbidity have
previously been evaluated in a separate publica-
tion.13 Long-term patency evaluation will require
continued surveillance of these patients.
The risk of neurologic morbidity by PTAS does
not appear to be reduced. The rate of total nonneu-
rologic morbidity, including access site hematoma,
cardiac complication, pulmonary dysfunction, and
renal failure, also appears to be higher than the rate
for CEA.13 The concern about a higher minor mor-
bidity rate associated with this technique should not
be discounted. Because the significance of minor
complications has not been established, we chose to
evaluate these complications on the basis of the
additional costs associated with their hospitaliza-
tions. All morbidity in this series is not associated
with additional hospitalization or costs (only four of
the seven strokes in the PTAS group required addi-
tional hospitalization). The hospitalization-extend-
ing complication rate is higher in the PTAS group at
19.2% versus 14.6% for the CEA group, but is not
statistically significant (Table II).
When further analysis is done to evaluate for the
lowest cost comparison between the CEA and the
PTAS group, we found that PTAS still costs more by
25%. This additional cost seems most related to the
difference between the procedure in the cardiac
catheterization laboratory as compared with operat-
Fig. 4. Cost comparison between uncomplicated and complicated admissions.
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lished and a clinical trial is considered, one must
consider the financial implications of undertaking a
randomized trial and the actual cost of the two
forms of therapy. Previously reported data do not
support near equivalency of PTAS to CEA.9,13
These cost data do not suggest that PTAS can be
done at a lower cost than CEA.
This analysis has been based on charges that our
hospital assesses for specific use of services.
Theoretically, cost data would be more accurate to
determine the difference in the cost but is not
obtainable as a result of current accounting meth-
ods. As the technical aspects of the procedure are
improved and the time required is shortened,
charges associated with the PTAS procedure may be
further reduced. However, the cost of medical
implants and monitoring equipment used for PTAS
significantly increases the cost of the entire proce-
dure.
In addition, preprocedure arteriography carries a
significant cost and can be reduced in both groups.
This will likely reduce the cost of both procedures in
a similar fashion. Currently, preprocedure arteriog-
raphy is used in all cases before carotid angioplasty,
although it is sometimes obtained from an outside
institution and then used as a baseline study. In this
study, 65% of PTAS admissions underwent diagnos-
tic arteriography during the same hospitalization.
Arteriography is used in most cases before CEA at
our institution, but only 62% of the CEA admissions
had arteriography performed at the same hospital-
ization. These arteriography charges are included in
the radiology charges portion of our analysis and
represent a similar distribution in both groups.
Elimination of this evaluation step and a subsequent
cost savings requires a well-established vascular lab-
oratory that can characterize these lesions based on
ultrasound criteria. Ideally, after a stenosis is identi-
fied by noninvasive means, carotid arteriography and
angioplasty could be undertaken at the same time,
during the same arterial puncture, by the same oper-
ator. Similarly, for CEA patients operative therapy
can be undertaken without angiography after ultra-
sound criteria or other methods accurately identify
an appropriate lesion.
Finally, the length of stay is shown to be some-
what shorter with the PTAS group. As our outpa-
tient management of CEA patients has improved,
we have tended to reduce postoperative hospital
stay. Discharge on the first postoperative day after
CEA has become an acceptable clinical prac-
tice.14,15 Neither outpatient endarterectomy nor
outpatient angioplasty have been established as
routine postprocedure care. It has been reported that
24% of angioplasty patients require additional treat-
ment for hypotension or bradycardia within the first
24 hours after the stent is placed.13 For this reason,
we target that both PTAS and CEA patients will
routinely be discharged on the first day after the pro-
cedure when all events are uncomplicated.
CONCLUSION
PTAS for the treatment of carotid stenosis can-
not currently be justified on the basis of reduced
costs alone when compared with CEA. Coupled
with previously reported data of higher combined
morbidity and mortality rates, the justification for a
prospective randomized trial comparing these two
methods must be questioned.
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Dr. Hugh G. Beebe (Toledo, Ohio). The authors
have compared two contemporary patient populations in
an institution that currently has the largest experience in
the United States with carotid angioplasty and stenting
and found that their hospital charges were about 29%, or
$8470 greater, in the stented group. They also had a high-
er stroke and death rate, 8.7%, for stenting in contrast to
3.0% after CEA—not yet statistically significant, but
almost certainly because of sample size.
The authors’ efforts carry with them the burden of
real-world imperfections in clinical research, and in this
case they are multiple: the bias of patient selection,
because these are not randomly allocated cohorts; imper-
fect methods of studying cost when one is forced to accept
the surrogate measure of charges; and an inherent bias, as
Dr. Jordan has already commented, in comparing an
established, familiar treatment with an evolving new treat-
ment. I would like to make some comments about each of
these three areas very briefly to ask some specific ques-
tions.
All patient populations are skewed by influences that
often cannot be described, let alone controlled for. If the
patients in the current study are typical of the previous
University of Alabama–Birmingham (UAB) experience,
the majority of those treated by stenting were self-referred
by cardiologists and a high percentage of them were
asymptomatic. The severity and distribution of atheroscle-
rotic disease and the expected morbidity rates of treatment
are different for asymptomatic patients than they are for
patients who have neurologic symptoms. Can the authors
tell us the percentage of asymptomatic patients in the two
cohorts?
Now, the use of charges to study cost is, well, maybe a
little like studying cheerleaders when you really want to
know the score of the game. It would be unacceptable
except for the fact that most hospitals don’t know what
things cost. The problem is that the ratios of charges to
cost that are used by many are not the same throughout
different parts of a hospital. For example, in normal ward
care, cost and charges are usually about equal. But in pro-
cedure rooms, cost and charges are very different, often
50% greater charges than for costs. So can the authors tell
us what the cost-to-charge ratio is for the procedure
rooms where the angioplasty and stenting are done and
for the operating room where the operations are done?
What percentage of your carotid surgery is performed
with the patient under general anesthesia? Why not
include professional fees when we’re talking about the cost
of this? I’m sure we all want to know. Interestingly
enough, the Health Care Financing Administration is on
record in public documents saying they don’t want to pay
for this. How are these professional fee questions being
resolved in your institution for carotid stenting?
The authors have compared CEA with stenting in the
most experienced group in the United States, but they are
still using in their stenting experience devices that are
adapted from other uses. It is argued by them that the
technology itself is evolving, and when it is specifically
designed for carotid use the cost may come down. What
percentage of your CEA patients underwent the operation
with decision making on the basis of duplex scans alone
without arteriography?
The authors are to be commended for challenging
those who are pursuing the alternative of carotid angio-
plasty to attend to the issues of cost. It turns out that
strokes are extremely expensive, particularly major ones.
The annual direct cost of a single stroke will pay for some-
where between 10 and 15 CEAs. But we must never dis-
cuss cost without including effectiveness. We note that the
stroke rate in this study was 7.7% for stents and 1.5% for
CEA. It can be argued that nothing is cheaper than get-
ting it right the first time.
Dr. William D. Jordan, Jr. Thank you, Dr. Beebe. I
think your comments today are very much appreciated. I
gathered five questions from that discussion, and I’ll try to
address each one of those.
First, the indications for treatment were similar
between the two in our analysis. Specifically, 35% to 40%
of patients were asymptomatic. The trial was initiated at
UAB for symptomatic lesions in early 1994. When the
ACAS paper was published, indications were expanded
to include asymptomatic patients. I do agree that we do
not have a randomized group. These groups are treated
on the basis of referral patterns, and most angioplasty
patients are referred by cardiologists or other interven-
tionalists who identify carotid lesions. At times, these
patients do come from surgeons in other locations who
consider this patient high-risk for surgery.
Your second question addressed the issue of cost
versus charge, and that is always an important topic in
this type of paper. Unfortunately, we were not able to
track our cost. Currently, our hospital is in a transition
DISCUSSION
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tation. In my opinion, it should blunt some of the enthusi-
asm expressed by the interventionalists for this procedure.
One other important consideration, however, as we seek
objective evaluation of this new interventional procedure is
the use of randomized clinical trial methods. Currently, there
are two groups in this country pursuing that goal. Your insti-
tution is a participant in the CREST study group, the
“Carotid Revascularization: Endarterectomy versus Stent
Trial.” Recognizing that the CREST protocol requires an
extensive credentialing period or phase I trial on the feasibil-
ity and safety of carotid balloon angioplasty and stenting
proceeding with randomization against carotid endarterec-
tomy, this method must be included as a consideration for
the future. Based on our work over the past 18 months with
the CREST study group, I have several questions.
First, how are patients referred for carotid revasculariza-
tion at UAB? For example, do you receive a consultation on
these procedures before they are performed by the cardiolo-
gy group?
Second, are you or the cardiologists using preprocedur-
al and postprocedural duplex scans and computed tomo-
graphic or magnetic resonance brain imaging? Can you add
any information on the incidence of embolic complications
associated with the catheter-based procedure?
And third, can you also describe quality control proce-
dures at UAB? Are complications from these cases presented
at a Vascular or Cardiology Morbidity/Mortality confer-
ence? How are complications discussed, and what impact
does that have on the patients’ informed consent?
These are important data, and I thank you for bringing
them to our attention.
Dr. Jordan. Thank you, Dr. Hobson. I agree that in
terms of looking at randomized trials that, again, safety
data need to be assessed. The UAB data are a wonderful
opportunity for that safety evaluation and should undergo
very critical review before any such trial is embraced.
These data represent our review based on the chart infor-
mation. One can also argue that it has a surgical bias, here
at a surgical meeting, presented by a surgeon, but again,
still important information. Let me answer your other
questions now.
Specifically, consultation for the surgeons at our institu-
tion has not been routine. There have been surgeons
involved on the panel that reviews the entire trial; that was
initially a neurosurgeon, and then I became involved with
that review on a delayed basis. Now, consultation only occurs
on selected patients based on the patient’s request when they
ask for further surgical opinion.
In terms of duplex evaluation, there is a set protocol for
percutaneous transluminal angioplasty, including preproce-
dural and postprocedural duplex evaluation. Sometimes
brain imaging, either computed tomographic or magnetic
resonance imaging, is done on an inpatient or outpatient
basis. It is not exactly clear whether those charges are incor-
porated into these hospital charges or whether they are done
as an outpatient. But realistically, the surgeons try not to add
additional charges unless they are clinically indicated.
phase of how they are tracking the cost, and so we were
not able to get that specific for these groups.
You asked an additional question about professional
fees. These fee charges are generated from offices separate
from the hospital business office. The hospital business
office was our primary source for charge data in these
patients. Professional fees are generated for the
endarterectomy group separate from the hospital business
office, and the professional fees for angioplasty are not
consistent. I thought it was most important then to eval-
uate hospital charges only in the face of these inconsisten-
cies. One can argue that there is another weakness because
we may have two professional fees in the endarterectomy
group if you count the anesthesiologist. Currently, there is
only one professional fee that may be assessed towards the
angioplasty group.
You asked about the type of anesthesia that we use. This
is dictated by the surgeon, and there were three different
surgeons who were involved. If I looked at the entire
endarterectomy group, somewhere between 15% and 20%
of patients underwent the operation under local anesthesia.
The type of anesthetic is not necessarily related to a patient’s
risk stratification as it is to the surgeon’s preference.
Finally, you asked about the issue of minor stroke and
the discussion and the cost associated with it. This ques-
tion is a very important topic because minor strokes can be
discounted as not being that important, perhaps the same
way that interventionalists report that surgeons discount
cranial nerve injuries because we do not always consider
them that significant. We decided in this paper to look at
what events extended a hospitalization. And while I may
not be able to address a direct cost in terms of a disability
cost to a patient, I could evaluate a financial impact in
terms of what it would cost in hospital dollars if they did
have a complication. When considering our original data,
there were 10 patients in the angioplasty group who had
extra hospital days for unclear reasons who were later
excluded in the uncomplicated group for PTAS. I could
not identify on chart review why exactly these patients
were there for extra hospital days, whether they simply had
the “weak and willies” and could not be discharged or
whether they had some other deficit that was hard to iden-
tify by chart review. Our analysis offers some attempt to
label whether or not a minor stroke is important in that it
may extend hospitalization. By contrast, you will notice
that only four of the seven patients with “neurologic
deficits” had actual additional hospital days. That means
three were minor enough that they did not stay beyond
four postprocedure days. So a minor stroke might be sim-
ply a hand weakness or arm weakness that does not lead to
prolonged rehabilitation, but I still think it is significant
enough that we ought to track it and know it. This has
been our surgical standard for years in the past on how we
evaluate our own surgical therapy. That standard ought to
be applied when evaluating any new modes of therapy.
Dr. Robert W. Hobson II (Newark, N.J.). I want to
congratulate Dr. Jordan and his colleagues for their presen-
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Perhaps the cardiologist or the interventionalist may pursue
more brain imaging because of their training and evaluation
of this different clinical disease, whereas we are more com-
fortable doing these procedures without brain imaging.
Finally, to address the embolic problem that may
occur. Again, that could be assessed afterwards by mag-
netic resonance imaging, but we have also used tran-
scranial Doppler monitoring. There are some data avail-
able that suggest that transcranial Doppler monitoring
shows a higher number of high-intensity transients, or
emboli that occur with balloon angioplasty; a statistical-
ly significant higher number than what occurs with
endarterectomy.
Finally, the quality control is mainly centered on the
Institutional Review Board at this time. We, as a sepa-
rate group of clinicians, have periodic meetings to
review the information. And I cannot stand here and tell
you that there is complete agreement between all the
investigators about the application of this method of
treatment.
Dr. Keith D. Calligaro (Philadelphia, Pa.). I rise also to
point out one of the problems with performing a random-
ized study, specifically concerning cost analysis. This issue has
to do with how patients are worked up and then how they
are treated. At our institution, as at many others, we are
operating on the basis of duplex scan only without any arte-
riogram in 90% of our cases, performed with the patient
under cervical block anesthesia without costly electroen-
cephalographic monitoring. The patients are transferred to
the floor 4 hours later in 90% of cases. Most are being dis-
charged the next day. I realize this is very controversial.
But if you are going to be performing a randomized
study, I think those aspects of performing a very cost-
effective CEA need to be taken into account.
Dr. Jordan. Again, after reviewing these data, we also
have undertaken some measures that you could argue
reduce cost. In this series we never said, “Well, we need to
cut down on the cost, let’s get this patient discharged
sooner.” It is our practice now that it’s more routine to go
home on the second postoperative day, and many go
home on the first postoperative day. Early discharge is
used for selected patients who live close by and meet spe-
cific criteria. So we do pursue that cost-saving measure.
I perform most of my CEAs with the patient under
local anesthesia or under cervical block. We do not use the
intensive care unit routinely. Most of our patients go to a
routine ward. Again, that policy is dictated very much by
the surgeon. And we have had some modification of our
clinical practice as we look at these data, and perhaps in
the future we will see a lower charge.
Now, the charge data here, you might argue, are high-
er than those seen at other hospitals around the country
or other locations. Again, this may be artificially inflated
because it is charge, not cost. There may be regional eco-
nomic factors that affect charges for these medical proce-
dures. This series may represent a more realistic picture of
medical cost because it is a retrospective analysis and no
specific measures were pursued to reduce cost.
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